Company Overview - Envista (NVST) is expected to report a year-over-year increase in earnings, with a consensus estimate of $0.24 per share, reflecting a change of +118.2% [3] - Revenues are anticipated to be $641.45 million, which is a 1.3% increase from the previous year [3] Earnings Expectations - The earnings report is scheduled for July 31, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Most Accurate Estimate for Envista is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.65%, suggesting a bearish outlook from analysts [12] - Despite the negative Earnings ESP, Envista holds a Zacks Rank of 2, complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Envista exceeded the expected earnings of $0.20 per share, achieving $0.24, which was a surprise of +20.00% [13] - Over the past four quarters, Envista has beaten consensus EPS estimates three times [14] Industry Context - InMode (INMD), another player in the Zacks Medical - Products industry, is expected to post earnings of $0.43 per share, indicating a year-over-year change of +26.5% [18] - InMode's revenues are projected to be $95.5 million, up 10.5% from the previous year [18] - The consensus EPS estimate for InMode has been revised down by 9.8% over the last 30 days, and it currently has an Earnings ESP of 0% with a Zacks Rank of 5 [19]

Core Viewpoint - Investors in the Medical - Products sector should consider Envista (NVST) and Abbott (ABT) for potential value opportunities, with NVST currently presenting a more attractive option based on various valuation metrics and earnings outlook [1][3][7]. Valuation Metrics - NVST has a forward P/E ratio of 18.81, while ABT has a higher forward P/E of 24.16, indicating that NVST may be undervalued compared to ABT [5]. - The PEG ratio for NVST is 1.23, suggesting a better valuation relative to its expected earnings growth compared to ABT's PEG ratio of 2.36 [5]. - NVST's P/B ratio stands at 1.09, significantly lower than ABT's P/B ratio of 4.41, further indicating NVST's relative undervaluation [6]. Earnings Estimate Revisions - NVST has experienced stronger estimate revision activity, which is a positive indicator for its earnings outlook compared to ABT [3][7]. - The Zacks Rank system rates NVST as 2 (Buy) and ABT as 3 (Hold), reflecting a more favorable earnings estimate revision trend for NVST [3]. Value Grades - NVST has been assigned a Value grade of B, while ABT has a Value grade of C, highlighting NVST's superior valuation metrics [6].

Core Viewpoint - Envista Holdings Corporation will report its financial results for the second quarter of 2025 on July 31, 2025, with a conference call scheduled for 2:00 PM PT to discuss these results [1]. Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [4]. - The company offers a comprehensive portfolio that includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [4]. - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [4]. Conference Call Details - The conference call will be accessible via a dial-in number, with a U.S. number of 1-800-836-8184 and an international number of +1 646-357-8785, starting a few minutes before the call [2]. - A replay of the webcast will be available shortly after the presentation concludes, and related materials will be posted on the "Investors" section of Envista's website [3].

Core Viewpoint - The comparison between Envista (NVST) and Abbott (ABT) indicates that NVST may offer better value for investors based on various financial metrics and rankings [1][3]. Valuation Metrics - Envista has a forward P/E ratio of 18.81, while Abbott's forward P/E is significantly higher at 26.65 [5]. - The PEG ratio for Envista is 1.23, indicating a more favorable valuation in relation to its expected earnings growth compared to Abbott's PEG ratio of 2.61 [5]. - Envista's P/B ratio stands at 1.08, contrasting with Abbott's P/B ratio of 4.87, further suggesting that Envista is undervalued relative to its book value [6]. Zacks Rank and Style Scores - Envista holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Abbott has a Zacks Rank of 3 (Hold) [3]. - In the Value category, Envista receives a grade of B, whereas Abbott is graded C, highlighting Envista's stronger position for value investors [6].

Core Insights - Envista Holdings Corp. (NVST) is positioned for robust future growth through global commercial organization expansion and deeper market penetration [1][3] - The company is actively assessing strategic acquisitions to complement its portfolio and enter new economic sectors [1][5] - Strong solvency is indicated by cash reserves and low debt levels, although currency fluctuations pose challenges [1][7][10] Financial Performance - NVST stock has gained 9.4% over the past year, outperforming the industry and S&P 500 growth rates of 8.4% and 9.2%, respectively [2] - The company has a market capitalization of $3.12 billion and an earnings yield of 5.4%, significantly higher than the industry's 0.5% [2] - In the last reported quarter, NVST achieved an earnings surprise of 20% [2] Market Expansion - Envista is focusing on international market expansion, with key markets in Europe, Asia, the Middle East, and Latin America [3] - The company enhances patient access to dental care by expanding clinical training and education, reaching over 250,000 dental professionals annually [3] - Positive growth was reported in North America, Japan, and emerging markets, while Europe experienced flat growth [4] Strategic Acquisitions - Recent acquisitions include Osteogenics Biomedical and Carestream Dental's Intraoral Scanner business, now operating as DEXIS [6][9] - These acquisitions aim to enhance NVST's product offerings and market reach [9] Solvency and Financial Strength - As of Q1 2025, NVST had cash and cash equivalents of $1.08 billion and current debt of only $116 million, indicating strong financial flexibility [7][9] - The debt-to-capital ratio decreased to 31.7%, reflecting improved financial health [7] Foreign Exchange Impact - Currency fluctuations negatively impacted sales by nearly 140 basis points year over year in Q1 2025 [10] - The company's operations are exposed to multiple foreign currencies, affecting sales, costs, and net income [10] Earnings Estimates - The Zacks Consensus Estimate for NVST's 2025 earnings per share (EPS) has increased by 3% to $1.03 [11] - Revenue estimates for 2025 are projected at $2.55 billion, indicating a 1.5% increase from the previous year [11]

Core Viewpoint - Envista (NVST) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Envista suggest an improvement in the company's underlying business, likely leading to increased stock prices [5][8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - Envista's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Envista is expected to earn $1.03 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 3.3% over the past three months [8].

Core Insights - Envista (NVST) and Abbott (ABT) are compared for investment value in the Medical - Products sector [1] - NVST has a stronger Zacks Rank of 2 (Buy) compared to ABT's 3 (Hold), indicating a more favorable earnings estimate revision trend for NVST [3] - Value investors utilize various metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - NVST has a forward P/E ratio of 18.49, while ABT has a forward P/E of 25.87, suggesting NVST is more attractively priced [5] - NVST's PEG ratio is 1.21, indicating better expected earnings growth relative to its price compared to ABT's PEG ratio of 2.52 [5] - NVST's P/B ratio is 1.06, significantly lower than ABT's P/B of 4.73, further supporting NVST's valuation advantage [6] Investment Outlook - NVST's improving earnings outlook enhances its attractiveness as a value investment option [7] - Based on the analysis of valuation metrics, NVST is positioned as the superior value opportunity compared to ABT [7]

Summary of Envista's Conference Call Company Overview - **Company**: Envista Holdings Corporation - **Industry**: Dental Products and Technologies Key Points and Arguments Industry Insights - The dental market remains fundamentally attractive despite macroeconomic uncertainties post-COVID, with no significant changes expected in the long-term growth trajectory of the industry [5][6] - The orthodontic segment is identified as the fastest-growing category, particularly in clear aligners, with a noted acceleration in the bracket and wire segment as well [8][10] - Consumables, which are largely reimbursed by insurance, are performing well, while the diagnostics and equipment categories are still contracting [10][11] Market Trends - Emerging markets are showing acceleration in demand, with Europe performing better than the U.S., which remains stable but slower [12] - Consumer confidence indicators have fluctuated, with recent improvements noted, suggesting potential optimism for the dental market in 2025 [14][16] Financial Performance - The implants division accounts for approximately 40% of revenue, with a recent contraction in the challenger segment attributed to fewer selling days [17][18] - Envista has focused on organic growth, investing an additional $25 million into high-margin businesses to drive performance [21][22] Strategic Focus - The company is prioritizing operational excellence and customer-centric leadership to improve its premium implant business, which has shown four consecutive quarters of growth but still has room for improvement [27][30] - There is a strong emphasis on R&D and innovation, particularly in the implant portfolio and regenerative solutions, with expectations for new products to impact growth by 2026 [34][36] Tariff Impact and Mitigation - Envista is actively managing tariff exposure, particularly concerning U.S. manufactured goods sold in China, and is shifting production to mitigate impacts [43][44] - The company anticipates a lagged impact from tariffs, with the ability to adjust supply chains over time [46][49] Pricing Strategy - Historically, dental companies have achieved 1-2% price increases, but recent years have seen challenges in this area. Envista is exploring ways to increase pricing to offset tariff impacts [58][59] - The company believes that moving supply across its global footprint will be a more significant lever for managing costs than solely relying on price increases [60][61] Future Outlook - Envista is optimistic about turning its Spark business profitable in the second half of the year, with a focus on automation and efficiency to improve margins [61][65] - The company is concentrating on the orthodontic segment for clear aligners, leveraging its existing market share and sales force to drive growth [68][69] Additional Important Content - The CEO highlighted the importance of operational excellence and clear accountability in driving performance improvements [30] - There is a recognition of the competitive landscape in the clear aligner market, with a focus on maintaining a disciplined pricing strategy [68][70]

BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET.A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/. ABOUT ENVISTA HOLDINGS CORPORATIONEnvista is a global family of more ...

Core Viewpoint - Envista Holdings Corporation reported a decline in adjusted earnings per share (EPS) for Q1 2025, but the results exceeded market expectations, indicating resilience despite challenges in certain segments [1][8]. Financial Performance - Adjusted EPS for Q1 2025 was 24 cents, down 7.7% year over year, but surpassed the Zacks Consensus Estimate by 20% [1]. - GAAP EPS was 10 cents compared to 14 cents in the prior-year period [1]. - Revenues totaled $616.9 million, a decrease of 1.1% year over year, yet exceeded the Zacks Consensus Estimate by 1.5% [3]. - Gross profit fell 5.7% year over year to $336 million, with a gross margin contraction of 267 basis points to 54.5% due to a 5.1% rise in cost of sales [4]. Segment Performance - Specialty Products & Technologies segment revenues were $400.3 million, down 2.1% year over year [3]. - Equipment & Consumables segment revenues increased by 0.8% year over year to $216.6 million [3]. - The company experienced growth in consumables, premium implants, and orthodontics (outside China) businesses [8]. Operational Metrics - Selling, general and administrative expenses decreased by 4.6% year over year to $271.7 million [4]. - Research and development expenses rose by 8.6% to $25.3 million [4]. - Operating profit was $39 million, down 18.9% year over year, with an operating margin contraction of 139 basis points to 6.3% [4]. Cash and Debt Position - Cash and cash equivalents at the end of Q1 2025 were $1.08 billion, slightly up from $1.07 billion at the end of Q4 2024 [5]. - Long-term debt increased to $1.30 billion from $1.28 billion in the previous quarter [5]. - Year-to-date net cash provided by operating activities was $0.3 million, a significant decrease from $40.3 million a year ago [5]. Future Guidance - The company reaffirmed its 2025 guidance, expecting core sales growth of 1-3% and adjusted EBITDA margins of approximately 14% [6]. - The Zacks Consensus Estimate for 2025 revenues is $2.53 billion, indicating a 0.8% increase from the previous year [6]. - Adjusted EPS is anticipated to be in the range of $0.95-$1.05, with the Zacks Consensus Estimate at $0.97 [7].